Andere Sprachen BiomX Inc.

Aktien

A2P9A0

US09090D1037

PHGE

Markt geschlossen - Nyse Andere Börsenplätze 22:10:00 03.05.2024			% 5 Tage	% 1. Jan.
0,3839 ^USD	-5,91 %		+9,69 %	+37,11 %

18.04.	Biomx Inc. ernennt Susan Blum zum Mitglied des Verwaltungsrats und zur Vorsitzenden des Prüfungsausschusses des Verwaltungsrats	CI
03.04.	Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases	24.04.
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)	23.04.
BiomX Announces the Appointment of Susan Blum to its Board of Directors	18.04.
Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	18.04.
BiomX : Introduction	04.04.
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure	04.04.
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	03.04.
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03.04.
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024	27.03.
Biomx Inc. Announces Board Changes	18.03.
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing	18.03.
BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC	15.03.
BiomX Inc. completed the acquisition of Adaptive Phage Therapeutics, Inc.	15.03.
Sector Update: Health Care Stocks Advance Wednesday Afternoon	06.03.
Sector Update: Health Care	06.03.
BiomX Shares Rally After Merger Deal With Adaptive Phage Therapeutics	06.03.
BiomX : Material Agreement - Form 8-K	06.03.
BiomX : Introduction	06.03.
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing	06.03.
BiomX Inc. announced that it expects to receive $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC	06.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BiomX Inc.

Aktien

A2P9A0

US09090D1037

PHGE

Andere Sprachen

Filter